Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus–related Lymphomas

Muncunill, Josep; Baptista, Maria Joao; Hernández-Rodríguez, Águeda; Dalmau, Judith; García, Olga; Tapia, Gustavo; Moreno, Miriam; Sancho, Juan‐Manuel; Martínez-Picado, Javier; Feliú, Evarist; Mate, José-Luís; Ribera, Josep‐Marǐa; Navarro, José-Tomás

doi:10.1093/cid/ciy542

Cited by 12 publications

(27 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In SSA, this biomarker has been most extensively evaluated in endemic Burkitt lymphoma and classic Hodgkin lymphoma, both of which are EBV positive in most cases . Plasma EBV is also a promising lymphoma marker in HIV‐positive patients, though its utility has been primarily explored in patients with EBV‐positive tumors.…”

Section: Discussionmentioning

confidence: 99%

High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition to the presence of EBV in lymphoma tissue, the virus can be detected in peripheral blood of patients with lymphoma. Some studies have suggested the usefulness of EBV load as a lymphoma biomarker with diagnostic and prognostic implications in PLWH [ 19 , 25 , 26 , 27 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical and Therapeutic Implications of Epstein–Barr Virus in HIV-Related Lymphomas

Verdu-Bou

Tapia

Hernández-Rodríguez

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

The incidence of lymphomas is increased in people living with HIV (PLWH). Aggressive B-cell non-Hodgkin lymphomas (NHLs) are the most common and are considered an AIDS-defining cancer (ADC). Although Hodgkin lymphoma (HL) is not considered an ADC, its incidence is also increased in PLWH. Among all HIV-related lymphomas (HRL), the prevalence of Epstein–Barr virus (EBV) is high. It has been shown that EBV is involved in different lymphomagenic mechanisms mediated by some of its proteins, contributing to the development of different lymphoma subtypes. Additionally, cooperation between both HIV and EBV can lead to the proliferation of aberrant B-cells, thereby being an additional lymphomagenic mechanism in EBV-associated HRL. Despite the close relationship between EBV and HRL, the impact of EBV on clinical aspects has not been extensively studied. These lymphomas are treated with the same therapeutic regimens as the general population in combination with cART. Nevertheless, new therapeutic strategies targeting EBV are promising for these lymphomas. In this article, the different types of HRL are extensively reviewed, focusing on the influence of EBV on the epidemiology, pathogenesis, clinical presentation, and pathological characteristics of each lymphoma subtype. Moreover, novel therapies targeting EBV and future strategies to treat HRL harboring EBV are discussed.

show abstract

“…Growing evidence supports the notion that cell-free plasma EBV DNA is a better marker than cellular (WB or PBMC) EBV DNA 17,28,29 . Considering that low-level reactivation of EBV can occur in the lymphoid tissues of immunocompromised patients without PTLD 17,28,30 , WB EBV DNA (including cellular EBV) is more likely to be detectable in such patients. Indeed, in a previous prospective trial, positive rate of EBV DNA in transplant patients without PTLD was higher in WB samples compared with plasma samples (42% vs. 3%) 28 .…”

Section: Discussionmentioning

confidence: 99%

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma

Kim

Cho

Sung

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The role of the Epstein-Barr virus (EBV) status in the blood for predicting survival in post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma (PTLD–DLBCL) is unknown. We evaluated the prognostic values of pre-treatment EBV-encoded small RNA (EBER) detected with in situ hybridization in tissues and EBV DNA in the whole blood (WB) and plasma in 58 patients with monomorphic PTLD–DLBCL after solid organ transplantation. There were no significant differences in the rates of overall response, complete response, and survival according to EBER EBV and WB EBV status. In contrast, patients with positive plasma EBV DNA had significantly lower rates of overall response (60.0% vs. 94.4%, P = 0.043) and complete response (40.0% vs. 88.9%, P = 0.019) as well as worse progression-free survival (PFS) (P = 0.035) and overall survival (OS) (P = 0.039) compared with patients with negative plasma EBV DNA. In multivariate analysis, plasma EBV DNA positivity was a significantly unfavorable prognostic factor for PFS [hazard ratio (HR) 4.92, 95% confidence interval (CI) 1.22–19.86, P = 0.025] and OS (HR 4.48, 95% CI 1.14–17.63, P = 0.032). Despite small number of 6 patients with plasma EBV positivity, plasma EBV DNA positivity might be more prognostic for survival than EBER or WB EBV DNA positivity in patients with monomorphic PTLD–DLBCL.

show abstract

Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus–related Lymphomas

Abstract: Plasma EBV-load can be used as biomarker and as prognostic factor in HIV-related lymphomas. The presence of EBV-load in plasma can be an early predictor of HIV-related lymphoma development.

Cited by 12 publications

References 34 publications

High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi

High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi

Clinical and Therapeutic Implications of Epstein–Barr Virus in HIV-Related Lymphomas

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma

Contact Info

Product

Resources

About